Natalia Holubec, LMFT in Plainfield, VT - Marriage & Family Therapist

Natalia Holubec, LMFT is a Marriage & Family Therapist based in Plainfield, Vermont. Natalia Holubec is licensed to practice in Vermont (license number 100.0134108) and her current practice location is 113 Bartlett Rd, Plainfield, Vermont. She can be reached at her office (for appointments etc.) via phone at (802) 279-7327.

NPI number for Natalia Holubec is 1386370815 and her current mailing address is 113 Bartlett Rd, Plainfield, Vermont. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1386370815.

Contact Information

	Natalia Holubec, LMFT
	113 Bartlett Rd, Plainfield, VT 05667-9658
	(802) 279-7327
	Not Available

Healthcare Provider's Profile

Full Name	Natalia Holubec
Gender	Female
Speciality	Marriage & Family Therapist
Location	113 Bartlett Rd, Plainfield, Vermont
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1386370815
Provider Enumeration Date: 07/27/2022
Last Update Date: 07/27/2022

Medical Identifiers

Medical identifiers for Natalia Holubec such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1386370815	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
106H00000X	Marriage & Family Therapist	100.0134108 (Vermont)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Natalia Holubec is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Natalia Holubec, LMFT 113 Bartlett Rd, Plainfield, VT 05667-9658 Ph: (802) 279-7327	Natalia Holubec, LMFT 113 Bartlett Rd, Plainfield, VT 05667-9658 Ph: (802) 279-7327

News Archive

Preliminary results from Celldex's CDX-011 Phase 2b breast cancer study

Celldex Therapeutics, Inc. today announced preliminary results from the Company's randomized Phase 2b EMERGE study of CDX-011 (glembatumumab vedotin) antibody drug conjugate in patients with glycoprotein NMB (GPNMB) expressing, advanced, heavily pretreated breast cancer. Preliminary results suggest that CDX-011 induces impressive response rates compared to current, available therapies in patients with advanced, refractory breast cancers with high GPNMB expression.

It's open enrollment. Here's what you need to know

California's annual health insurance enrollment season for individuals and families kicks off this week against a dramatic backdrop: the hotly contested presidential election; a pandemic raging out of control in much of the U.S.; and, on Nov. 10, a Supreme Court hearing of a case that could end the Affordable Care Act and strand millions without coverage.

Men should discuss risks, benefits with doctor before undergoing prostate-cancer screening

Men who undergo prostate-cancer screening should discuss with a doctor the uncertainties, risks and benefits of the test before it is performed, says Edward Partridge, M.D., president-elect of the American Cancer Society National Board of Directors and director of the University of Alabama at Birmingham Comprehensive Cancer Center.

Infinity voluntarily stops saridegib Phase 2 trial for chondrosarcoma

Infinity Pharmaceuticals, Inc. today announced interim data from its Phase 2, double-blind, randomized, placebo-controlled study of saridegib (IPI-926) in patients with metastatic or locally advanced, inoperable chondrosarcoma. The primary endpoint of the Phase 2 study was progression-free survival.

Common Sense Advisory's report highlights effects of health care reform on non-English speaking patients

With an estimated 50 million people who speak languages other than English at home, the United States health care system serves one of the most linguistically diverse patient populations in the world. A new report from market research firm Common Sense Advisory answers the question, "How will health care reform affect patients with limited English proficiency (LEP)?" The firm's new report, "Health Care Reform and Language Services," pinpoints 14 sections of "America's Affordable Health Choices Act of 2009" that will influence the nation's provision of health care interpreting and translation services.

Natalia Holubec, LMFT - Couples Therapy in Plainfield, VT